Support SRUK’s life-changing work today. You can also pay in your fundraising here
The focus of the discussions around scleroderma at The British Society for Rheumatology conference in Birmingham in 2017 was the impact upon the heart. The annual conference for researchers and healthcare professionals was held from 25 to 27 April and attracted over 2,000 delegates from over 50 countries.
SRUK joined UCL's Professor Chris Denton, who led a discussion on scleroderma and its effects on the heart and circulatory system. Dan Knight, who works at the Cardiac MRI Centre at the Royal Free Hospital, gave a presentation on the use of cardiac imaging to assess heart involvement in scleroderma. Pulmonary arterial hypertension occurs in about 10% of people with scleroderma and can lead to poor outcomes. It is thought that restricted blood supply to the heart and scarring, possibly related to inflammation, may play a role. Cardiac magnetic resonance enables scar tissue to be seen. There are a few types of imaging, one that uses contrast agents, and T1 and T2 mapping. Dr Knight's talk explained the background behind these techniques and how they can be incorporated into clinical practice.
Dr Knight was followed by Dr Gareth Padfield, cardiologist at Victoria Hospital in Fife, who discussed abnormal electrical activity in the heart. There is an increased risk of this in scleroderma, which may lead to a slow heart rate (bradycardia) or His-purkinjie disease, that can be identified by ECG, or even cardiac arrest. Dr Padfield reviewed the mechanisms of irregular heart rhythms in systemic sclerosis and related connective tissue diseases and explored future directions to improve the identification of people at risk, as well as the use of targeted anti-arrhythmic treatments.
Maya Buch, from the University of Leeds, concluded the discussion with her talk on the current management of cardiac scleroderma. This talk was based on the UK Systemic Sclerosis Study Group best practice recommendations that aim to develop pathways for the management of scleroderma-specific complications, including heart disease. The pathway provides a reference for all physicians managing people with scleroderma. Professor Buch advocates that people with scleroderma and cardiac involvement are managed within a multidisciplinary team that includes rheumatologists and cardiologists.
SRUK provided information about scleroderma to interested rheumatologists attending the BSR conference, and members of our team attended talks given by leading specialists about the latest advancements, raising the profile as ever of SRUK-funded research. This year, for example, three posters from the University of Manchester report the results of research we have funded. Please click here for up-to-date news on the SRUK-funded research that is happening now.